| Original language | English (US) |
|---|---|
| Pages (from-to) | 1284-1288 |
| Number of pages | 5 |
| Journal | Chest |
| Volume | 142 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2012 |
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Chest, Vol. 142, No. 5, 11.2012, p. 1284-1288.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Executive summary - Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients
T2 - American College of Chest Physicians evidence-based clinical practice guidelines
AU - Baughman, Robert P.
AU - Meyer, Keith C.
AU - Nathanson, Ian
AU - Angel, Luis
AU - Bhorade, Sangeeta M.
AU - Chan, Kevin M.
AU - Culver, Daniel
AU - Harrod, Christopher G.
AU - Hayney, Mary S.
AU - Highland, Kristen B.
AU - Limper, Andrew H.
AU - Patrick, Herbert
AU - Strange, Charlie
AU - Whelan, Timothy
N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Baughman's institution (University of Cincinnati) has received grants for research in sarcoidosis and idiopathic pulmonary fibrosis from Actelion Pharmaceuticals Ltd; Celgene Corporation; Cephalon, Inc; Centocor Ortho Biotech, Inc; Gilead Sciences, Inc; and InterMune. Dr Hayney has received grant support from the University of Wisconsin and the National Institutes of Health. She serves on the speakers' bureau for Merck Vaccines. Dr Patrick received a travel stipend from Omneotech, Inc; owns stock in pharmaceutical/medical device companies, including Human Economics, Rite Aid Corp, Numec, and Hospira, Inc; and is a member of the speakers' bureau for Gilead Sciences, Inc. Dr Strange has received grant monies and salary support from the National Institutes of Health to study cyclophosphamide and mycophenolate mofetil in scleroderma. He has received grant monies and salary support from Centocor Ortho Biotech, Inc, for the study of ustekinumab and golimumab in sarcoidosis. He has been a consultant for AstraZeneca; Uptake Medical; PneumRx, Inc; Pulmonx; Aeris Therapeutics; Talecris Biotherapeutics, Inc; CSL Behring; Baxter; Gilead Sciences, Inc; MedImmune, LLC; and Actelion Pharmaceuticals Ltd in the past 3 years. For the past 3 years, he has received speakers' bureau income from AstraZeneca; Talecris Biotherapeutics, Inc; Gilead Sciences, Inc; Actelion Pharmaceuticals Ltd; and Pfizer, Inc, and from the France Foundation for InterMune on topics not related to the subject of this article. Dr Whelan has received research support from Actelion Pharmaceuticals Ltd; Celgene Corporation; Centocor Ortho Biotech, Inc; and InterMune. He has also received consultant fees from InterMune. His contributions to this article were free from potential conflicts of interest related to these activities. Drs Meyer, Nathanson, Angel, Bhorade, Chan, Culver, Highland, and Limper and Mr Harrod have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2012/11
Y1 - 2012/11
UR - http://www.scopus.com/inward/record.url?scp=84868610096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868610096&partnerID=8YFLogxK
U2 - 10.1378/chest.12-1075
DO - 10.1378/chest.12-1075
M3 - Article
C2 - 23131936
AN - SCOPUS:84868610096
SN - 0012-3692
VL - 142
SP - 1284
EP - 1288
JO - Chest
JF - Chest
IS - 5
ER -